LDL Cholesterol Goals for High-Risk Patients

LDL Goals Based on Risk Category

The European Society of Cardiology recommends an LDL-C goal of <70 mg/dL for patients at very high cardiovascular risk, with an alternative goal of reducing LDL-C by at least 50% if baseline LDL-C is between 70-135 mg/dL 1, 2
The American Heart Association suggests that very high-risk patients, including those with established cardiovascular disease plus multiple major risk factors, severe and poorly controlled risk factors, multiple risk factors of metabolic syndrome, or acute coronary syndromes, should aim for an LDL-C goal of <70 mg/dL 3, 4
For high-risk patients, the American College of Cardiology recommends an LDL-C goal of <100 mg/dL, considered the minimal goal of treatment, with a reduction of at least 50% if baseline LDL-C is between 100-200 mg/dL 1, 5, 6

The Heart Protection Study and PROVE IT trial demonstrated that LDL-C of 100 mg/dL is not a threshold below which no further benefit occurs, with intensive LDL-C lowering showing reduced cardiovascular events compared to standard therapy 6, 7
Reducing LDL-C by 30% starting at 100 mg/dL can produce another 20-30% lowering in relative risk for coronary heart disease, with intensive lowering of LDL-C to well below 100 mg/dL reducing progression of coronary atherosclerotic lesions 6, 8

The American Heart Association recommends statin therapy as the first-line treatment to achieve LDL-C goals, with an adequate dose reducing LDL-C to <100 mg/dL and achieving at least a 30% lowering of LDL-C 5, 9
If treatment with statins does not achieve the goal, intensification with bile acid sequestrants or niacin is reasonable, according to the American College of Cardiology 5

Clinical trials with statin therapy have not identified significant side effects from LDL lowering per se, with the decision to achieve very low LDL levels based on evidence of benefit and recognition of a remote possibility of side effects 4
For patients who do not tolerate statins, LDL-C-lowering therapy with bile acid sequestrants and/or niacin is reasonable, as suggested by the American Heart Association 5

For patients with high triglycerides, non-HDL-C should be <130 mg/dL for high-risk patients and <100 mg/dL for very high-risk patients, according to the American College of Cardiology 5

The American Heart Association suggests that very low LDL-C targets (<70 mg/dL) are appropriate for very high-risk patients, including those with established cardiovascular disease plus multiple major risk factors, severe and poorly controlled risk factors, metabolic syndrome with high triglycerides, or acute coronary syndromes 10

The European Society of Cardiology indicates that no threshold exists below which cardiovascular benefit ceases—even patients achieving LDL-C <25 mg/dL continue to show risk reduction without significant safety concerns 11, 10
Intensive LDL-lowering to achieve very low levels can reduce major cardiovascular events, with the American College of Cardiology recommending aggressive LDL-lowering in very high-risk cardiovascular patients 10

Patients with PCSK9 loss-of-function mutations living with lifelong low LDL-C show no evidence of neurocognitive impairment, higher incidence of diabetes, cataracts, or stroke, according to the European Heart Journal 11
Pooled data from clinical trials showed patients with LDL-C <25 mg/dL had no significant difference in gonadal hormones or fat-soluble vitamins A, D, and K 11

The American College of Cardiology recommends evaluating for severe heart failure (cardiac cachexia) when encountering unexplained low total cholesterol 12

The American Heart Association suggests determining treatment status and obtaining a fasting lipid panel to calculate LDL-C, HDL-C, and triglycerides for patients on lipid-lowering therapy 13, 12
For very high-risk patients on lipid-lowering therapy, the American College of Cardiology recommends continuing therapy if LDL-C <70 mg/dL, with adequate HDL-C levels 10, 14

In adult patients, an HDL‑cholesterol concentration < 35 mg/dL is linked to a higher risk of cardiovascular events, independent of LDL‑C or total‑cholesterol levels. Evidence: observational data. 15

When evaluating lipid profiles, LDL‑C should be calculated with the Friedewald formula: LDL = Total cholesterol − (HDL + Triglycerides ÷ 5) (valid when triglycerides are ≤ 400 mg/dL). This provides a reliable estimate for clinical decision‑making. Evidence: standard clinical method. 15

Evaluation of unexplained low total cholesterol should include liver function tests to detect hepatic disorders that may impair endogenous cholesterol synthesis. Evidence: guideline‑based recommendation. 15